Prometic Pharma Smt Limited

Prometic Biosciences Inc.

Prometic Biotherapeutics, Inc.

Liminal Biosciences Limited

Liminal R&d Biosciences Inc.

Pierre Laurin

Lyne Gagnon

Boulos Zacharie

Brigitte Grouix

Christopher L Penney

Shaun Abbott

Lilianne Geerts

François Sarra-Bournet

Martin Leduc

Jean-François Bienvenu

Jean-Francois Bienvenu

Jean Barabe

Martin Robitaille

Karen Thibaudeau

Valérie Perron

Stacy Plum

The present invention concerns the use of plasminogen, a variant thereof, or an analog thereof having a plasminogen activity, for the prevention or treatment of a condition or a disease that is characterized with an increased PAI-1 level. The conditions and diseases that are characterized with an increased PAI-1 level, are regrouped within two categories: the diseases associated with an impaired vascular or tissue remodeling capacity, and the metabolic and hormonal disorders associated with an increased PAI-1 level.

Plasminogen treatment of conditions associated with PAI-1 overexpression

The present invention relates to compounds of: or a pharmaceutically acceptable salt thereof, wherein A is Calkyl, Calkyl, Calkenyl, Calkenyl, C(O)&#x2014;(CH)&#x2014;CHor CH(OH)&#x2014;(CH)&#x2014;CHwherein n is 3 or 4; Ris H, F or OH; Ris Calkyl, Calkyl, Calkenyl, Calkenyl, C(O)&#x2014;(CH)&#x2014;CHor CH(OH)&#x2014;(CH)&#x2014;CHwherein n is 3 or 4; Ris H, F, OH or CHPh; Ris H, F or OH; Q is

Substituted aromatic compounds and related method for the treatment of fibrosis

Subjects of the invention are a method of plasminogen supplementation in a plasminogen-deficient subject, and method for the treatment of plasminogen-deficiency in a plasminogen-deficient subject. These methods comprise administering to the plasminogen-deficient subject a dose of plasminogen, and more particularly Glu-plasminogen, for increasing the subject plasminogen activity level by at least about 1%, and more particularly by at least 10%, of the normal plasminogen activity and for maintaining the plasminogen activity level over a supplementation period or a treatment period. The plasminogen-deficient subject of the present invention may suffer from Type-I, Type-II plasminogen-deficiency or an acquired deficiency.

Plasminogen replacement therapy for plasminogen-deficiency

The present invention relates to substituted aromatic compounds for use in prevention or treatment of various fibrotic diseases and conditions in subjects, including pulmonary fibrosis, liver fibrosis, skin fibrosis and cardiac fibrosis, where the compound has the following formula: or a pharmaceutically acceptable salt thereof, wherein

Substituted aromatic compounds for the treatment of pulmonary fibrosis, liver fibrosis, skin fibrosis and cardiac fibrosis

Described herein are compounds of Formula I, or pharmaceutically acceptable salts thereof, or combinations thereof, as well as uses thereof. Such uses include promoting tissue self-repair or tissue regeneration of an organ, stimulating the generation of tissue growth, modulating (e.g., increasing) the level of a tissue-repair marker, treating physical injury in an organ, tissue or cell, promoting wound healing, as well as anti-aging applications. Corresponding compositions, methods, kits, and uses are also described. Formula I wherein A is Calkyl, Calkyl, Calkenyl, Calkenyl, C(O)&#x2014;(CH)&#x2014;CHor CH(OH)&#x2014;(CH)&#x2014;CHwherein n is 3 or 4; Ris H, F of OH; Ris H, F, OH, Calkyl, Calkyl, Calkenyl, Calkenyl, C(O)&#x2014;(CH)&#x2014;CHor CH(OH)&#x2014;(CH)&#x2014;CHwherein n is 3 or 4; Ris H, F, OH, or CHPh; Ris H, F or OH; Q is 1) (CH), C(O)OH wherein m is 1 or 2 2) CH(CH)C(O)OH, 3) C(CH)C(O)OH, 4) CH(F)&#x2014;C(O)OH, 5) CF&#x2014;C(O)OH or 6) C(O)&#x2014;C(O)OH.

Substituted aromatic compounds and pharmaceutical compositions for tissue self-repair and regeneration

The present invention relates to compounds of: or a pharmaceutically acceptable salt thereof, whereinA is Calkyl, Calkyl, Calkenyl, Calkenyl, C(O)&#x2014;(CH)&#x2014;CHor CH(OH)&#x2014;(CH)&#x2014;CHwherein n is 3 or 4;Ris H, F or OH;Ris Calkyl, Calkyl, Calkenyl, Calkenyl, C(O)&#x2014;(CH)&#x2014;CHor CH(OH)&#x2014;(CH)&#x2014;CHwherein n is 3 or 4;Ris H, F, OH or CHPh;Ris H, For OH;Q is

Described herein are compounds of Formula I, or pharmaceutically acceptable salts thereof, or combinations thereof, as well as uses thereof. Such uses include promoting tissue self-repair or tissue regeneration of an organ, stimulating the generation of tissue growth, modulating (e.g. increasing) the level of a tissue-repair marker, treating physical injury in an organ, tissue, or cell, promoting wound healing as well as anti-aging applications. Corresponding compositions, methods and uses are also described. Formula I wherein A is Calkyl, Calkyl, Calkenyl, Calkenyl, C(O)&#x2014;(CH)&#x2014;CHor CH(OH)&#x2014;(CH)&#x2014;CHwherein n is 3 or 4; Ris H, F of OH; Ris H, F, OH, Calkyl, Calkyl, Calkenyl, Calkenyl, C(O)&#x2014;(CH)&#x2014;CHor CH(OH)&#x2014;(CH)&#x2014;CHwherein n is 3 or 4; Ris H, F, OH, or CHPh; Ris H, F or OH; Q is 1) (CH),C(O)OH wherein m is 1 or 2 2) CH(CH)C(O)OH, 3) C(CH)C(O)OH, 4) CH(F)&#x2014;C(O)OH, 5) CF&#x2014;C(O)OH or 6) C(O)&#x2014;C(O)OH. 

The present invention relates to compounds of: or a pharmaceutically acceptable salt thereof, wherein A is Calkyl, Calkyl, Calkenyl, Calkenyl, C(O)&#x2014;(CH)&#x2014;CHor CH(OH)&#x2014;(CH)&#x2014;CHwherein n is 3 or 4; Ris H, F or OH; Ris Calkyl, Calkyl, Calkenyl, Calkenyl, C(O)&#x2014;(CH)&#x2014;CHor CH(OH)&#x2014;(CH)&#x2014;CHwherein n is 3 or 4; Ris H, F, OH or CHPh; Ris H, F or OH; Q is 1) (CH)C(O)OH wherein m is 1 or 2, 2) CH(CH)C(O)OH, 3) C(CH)C(O)OH, 4) CH(F)&#x2014;C(O)OH, 5) CF&#x2014;C(O)OH, or 6) C(O)&#x2014;C(O)OH; and compositions comprising the same and the method using the same for the prevention or treatment of various fibrotic diseases and conditions in subjects, including pulmonary fibrosis, liver fibrosis, skin fibrosis, renal fibrosis, pancreas fibrosis, systemic sclerosis, cardiac fibrosis or macular degeneration.

The present invention relates to substituted aromatic compounds for use in prevention or treatment of various fibrotic diseases and conditions in subjects, including pulmonary fibrosis, liver fibrosis, skin fibrosis and cardiac fibrosis, where the compound has the following formula: or a pharmaceutically acceptable salt thereof, wherein A is Calkyl, Calkyl, Calkenyl, Calkenyl, C(O)&#x2014;(CH)&#x2014;CHor CH(OH)&#x2014;(CH)&#x2014;CHwherein n is 3 or 4; Ris H, OH or F; Ris H, OH, F or CH&#x2014;OH; Ris H, OH, F or CHPh; Ris H, OH or F; Q is 1) (CH)C(O)OH wherein m is 1 or 2, 2) CH(CH)C(O)OH, 3) C(CH)C(O)OH, 4) CH(F)&#x2014;C(O)OH, 5) CF&#x2014;C(O)OH, or 6) C(O)&#x2014;C(O)OH. 

Substituted aromatic compounds for the treatment pulmonary fibrosis, liver fibrosis, skin fibrosis and cardiac fibrosis

Use of a composition comprising a compound of any of formulae I, II, Ila, III and Illa; or a combination thereof wherein each Ris independently Calkyl; A and B are independently H or CO&#x2014;R; Ris H or Calkyl; M is a metal monocation (k=1) or dication (k=2); Y is 0 or NH; and Z is 0, NH, CHO or a bond; for the manufacture of a medicament for stimulating erythropoiesis. Preferably, the composition further comprises human erythroporietin. 

Medium-chain length fatty acids, glycerides and analogues as stimulators of erythropoiesis

Phenylketone carboxylate compounds of Formula I, wherein n=2-6; R&#x2550;C(0); &#x2014;OC(O)&#x2014; or &#x2014;CH(OH)&#x2014;; A is (CH2)mCOOH, W(CH2)mCOOH or YCH(COOH)((CH2)pCH3) when B is Ft B is (CH2)mCOOH, W(CH2)mCOOH or YCH(COOH)((CH2)pCH3) when A is Ft or A and B form a 5-7 membered cycloalkyl substituted with COOFt W=0, S or NFt Y=0,S,NH or CH2; m=0-2; p=1-7; have been prepared. These compounds and their pharmaceutically acceptable salts have beneficial therapeutic effects to prevent or treat a condition related to (l) blood disorders, (ii) inflammation related diseases, (iii) renal disorders and/or renal disorders complications, or (iv) fibrosis-related organ dysfunction. 

Phenylketone carboxylate compounds and pharmaceutical uses thereof

New uses for phenylketone carboxylate compounds and substituted aromatic compounds of Formula I, Formula I.1, Formula I.2, Formula IA, Formula IB, Formula IC and Formula II and their pharmaceutical acceptable salts for the treatment of cancer. The use of a combination of two of these compounds is described and the use of the combination of one of these compounds with an anticancer agent such as decarbazine, doxorubicin, daunorubicin, cyclophosphamide, busulfex, busulfan, vinblastine, vincristine, bleomycin, etoposide, topotecan, irinotecan, taxotere, taxol, 5-fluorouracil, methotrexate, gemcitabine, cisplatin, carboplatin and chlorambucil.

Compounds and compositions for the treatment of cancer

A composition and method for promoting neutrophil survival and activation such as the treatment of neutropenia arising as an undesirable side effect of chemotherapy and radiation therapy. A composition containing medium-chain fatty acids, such as Capri acid or caprylic acid, or salts or triglycerides thereof, or mono- or diglycerides or other analogues thereof or medium-chain triglycerides (MCT) is administered to a human or animal needing treatment in an amount sufficient to reduce or eliminate neutropenia. The composition is administered in an amount effective to treat the disorder. The methods are also useful in the management of bone narrow transplantation and in the treatment of various neutropenic diseases.

Growing community of inventors

Ville Mont-Royal, Canada

Pierre Laurin